It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
As a hot topic today, ferroptosis is closely involved in the progression and treatment of cancer. Accordingly, we built a prognostic model around ferroptosis to predict the overall survival of OSCC patients. We used up to 6 datasets from 3 different databases to ensure the credibility of the model. Then, through differentially expressed, Univariate Cox, and Lasso regression analyses, a model composed of nine prognostic-related differently expressed ferroptosis-related genes (CISD2, DDIT4, CA9, ALOX15, ATG5, BECN1, BNIP3, PRDX5 and MAP1LC3A) were constructed. Moreover, Kaplan–Meier curves, Receiver Operating Characteristic curves and principal component analysis used to verify the model's predictive ability showed the model's superiority. To deeply understand the mechanism of ferroptosis affecting the occurrence, development and prognosis of OSCC, we performed enrichment analysis in different risk groups identified by the model. The results showed that numerous TP53-related, immune-related and ferroptosis-related functions and pathways were enriched. Further immune microenvironment analysis and mutation analysis have once again revealed the correlation between risk score and immunity and TP53 mutation. Finally, the correlation between risk score and OSCC clinical treatment, as well as Nomogram show the brilliant clinical application prospects of the prognostic model.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The Affiliated Stomatological Hospital of Nanchang University, Nanchang, China (GRID:grid.260463.5) (ISNI:0000 0001 2182 8825); The Key Laboratory of Oral Biomedicine, Nanchang, China (GRID:grid.260463.5); Jiangxi Province Clinical Research Center for Oral Diseases, Nanchang, China (GRID:grid.260463.5); The Affiliated Hospital of Jinggangshan University, Jian, China (GRID:grid.440809.1) (ISNI:0000 0001 0317 5955)
2 The Sixth Affiliated Hospital, Sun Yat-sen University, Department of Colorectal Surgery, Guangzhou, China (GRID:grid.488525.6)
3 Fenyi County people′s Hospital, Ophthalmology and Otorhinolaryngology, Xinyu, China (GRID:grid.488525.6)
4 The Affiliated Stomatological Hospital of Nanchang University, Nanchang, China (GRID:grid.260463.5) (ISNI:0000 0001 2182 8825); The Stomatology College of Nanchang University, Nanchang, China (GRID:grid.260463.5) (ISNI:0000 0001 2182 8825)